Head and neck squamous cell carcinoma (HNSCC) exhibits considerable variability in patient outcome. It has been reported that SOX2 plays a role in proliferation, tumor growth, drug resistance, and metastasis in a variety of cancer types. Additionally, SOX9 has been implicated in immune tolerance and treatment failures. SOX2 and SOX9 induce treatment failure by a molecular mechanism that has not yet been elucidated. This study explores the inverse association of SOX2/SOX9 and their distinct expression in tumors, influencing the tumor microenvironment and radiotherapy responses. Through public RNA sequencing data, human biopsy samples, and knockdown cellular models, we explored the effects of inverted SOX2 and SOX9 expression. We found that patients expressing SOX2LowSOX9High showed decreased survival compared to SOX2HighSOX9Low. A survival analysis of patients stratified by radiotherapy and human papillomavirus brings additional clinical relevance. We identified a gene set signature comprising newly discovered candidate genes resulting from inverted SOX2/SOX9 expression. Moreover, the TGF-β pathway emerges as a significant predicted contributor to the overexpression of these candidate genes. In vitro findings reveal that silencing SOX2 enhances tumor radioresistance, while SOX9 silencing enhances radiosensitivity. These discoveries lay the groundwork for further studies on the therapeutic potential of transcription factors in optimizing HNSCC treatment.
Human papillomavirus (HPV) is the main cause of anal carcinoma, whose incidence is rising globally, especially among men who have sex with men (MSM). This study estimated anal HPV prevalence, investigated genotype distribution, and identified associated factors among MSM in Brazil. The SMESH study, a multicenter cross-sectional survey (2019-2023), analyzed 1375 MSM (≥18 years) from nine Brazilian capitals using respondent-driven sampling. Participants completed questionnaires and provided self-collected anal samples for HPV detection. Weighted analyses were applied. Anal HPV prevalence was 72.4% (95% CI: 67.6-77.3), with 62.3% (95% CI: 56.9-67.8) harboring high-risk HPV and 36.4% (95% CI: 30.9-41.8) infected with quadrivalent vaccine types. MSM living with HIV (18.1%), compared to HIV-negative MSM, had higher overall (87.7% vs 69.6%, P < 0.001) and high-risk HPV prevalence (78.9 vs 58.9%, P < 0.001). Vaccinated MSM presented lower rates of quadrivalent vaccine types, particularly HPV 16. Younger age (25-34 years), frequent group sex, and regular drug use during sex were associated with HPV infection. The high prevalence of anal HPV among Brazilian MSM highlights the importance of expanding HPV vaccination coverage, particularly for HIV-positive MSM, and reinforces the need for gender-neutral vaccination of all girls and boys before sexual debut.